Teva Pharmaceutical Industries Limited (TLV:TEVA)

Israel flag Israel · Delayed Price · Currency is ILS · Price in ILA
10,000
-80 (-0.79%)
At close: Dec 25, 2025
22.67%
Market Cap116.00B
Revenue (ttm)55.55B
Net Income (ttm)2.36B
Shares Outn/a
EPS (ttm)2.04
PE Ratio49.14
Forward PE12.10
Dividendn/a
Ex-Dividend Daten/a
Volume1,384,820
Average Volume1,359,006
Open10,130
Previous Close10,080
Day's Range10,000 - 10,170
52-Week Range4,865 - 10,240
Beta0.67
RSI76.96
Earnings DateJan 28, 2026

About TLV:TEVA

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The com... [Read more]

Sector Healthcare
Founded 1901
Employees 35,686
Stock Exchange Tel Aviv Stock Exchange
Ticker Symbol TEVA
Full Company Profile

Financial Performance

In 2024, TLV:TEVA's revenue was $16.54 billion, an increase of 4.40% compared to the previous year's $15.85 billion. Losses were -$1.64 billion, 193.2% more than in 2023.

Financial numbers in USD Financial Statements

News

$100 Invested In Teva Pharmaceutical Indus 5 Years Ago Would Be Worth This Much Today

Teva Pharmaceutical Indus (NYSE: TEVA) has outperformed the market over the past 5 years by 13.95% on an annualized basis producing an average annual return of 27.15%. Currently, Teva Pharmaceutical ...

2 hours ago - Benzinga

Teva Pharmaceutical Stock Hits 52-Week High On Credit Ratings Lift

S&P upgraded Teva to BB+ and Moody's turned ... Full story available on Benzinga.com

1 day ago - Benzinga

S&P Global Ratings Upgrades Teva to ‘BB+’ Amid Strong Execution of Pivot to Growth Strategy; Moody’s Ratings Agency Revises Outlook to Positive

The two updates underscore Teva’s strong execution of its Pivot to Growth strategy and commitment to financial discipline. Moody’s affirmed Teva’s B1a rating and revised Teva’s outlook to positive fro...

1 day ago - Financial Post

S&P Global Ratings Upgrades Teva to ‘BB+' Amid Strong Execution of Pivot to Growth Strategy; Moody's Ratings Agency Revises Outlook to Positive

TEL AVIV, Israel, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that S&P Global Ratings ("S&P") has upgraded Teva's long-term issuer credi...

1 day ago - GlobeNewsWire

Billionaire Stanley Druckenmiller Sold Nvidia and Palantir and Piled Into One of Wall Street's Hottest Drug Stocks Ahead of 2026

Quarterly-filed Form 13Fs allow investors to track which stocks Wall Street's savviest money managers are buying and selling. Billionaire Stanley Druckenmiller dumped his fund's stakes in AI darlings ...

1 day ago - The Motley Fool

Piper Sandler Elevates TEVA Price Target to $40 with Overweight Rating | TEVA Stock News

Piper Sandler Elevates TEVA Price Target to $40 with Overweight Rating | TEVA Stock News

3 days ago - GuruFocus

Goldman Sachs Raises TEVA Price Target to $35, Maintains Buy Rating | TEVA Stock News

Goldman Sachs Raises TEVA Price Target to $35, Maintains Buy Rating | TEVA Stock News

5 days ago - GuruFocus

Insider Selling: Amir Weiss Unloads $371K Of Teva Pharmaceutical Indus Stock

Disclosed on December 18, Amir Weiss , Chief Accounting Officer at Teva Pharmaceutical Indus (NYSE: TEVA), executed a substantial insider sell as per the latest SEC filing. What Happened: A Form 4 fi...

6 days ago - Benzinga

Alvotech, Teva Secures U.S. License Entry Date For Eylea Biosimilar AVT06

(RTTNews) - Alvotech (ALVO) and Teva Pharmaceutical Industries Ltd. (TEVA) have secured a U.S. license entry date for AVT06, the proposed biosimilar to Regeneron's Eylea, setting the stage for a poten...

6 days ago - Nasdaq

Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®

REYKJAVIK, Iceland and TEL AVIV, Israel, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for...

6 days ago - GlobeNewsWire

My Top 10 Portfolio Holdings for 2026

It's been another banner year on Wall Street, with the Dow Jones Industrial Average, S&P 500, and Nasdaq Composite, respectively, higher by 14%, 16%, and 20% year-to-date. Although I've been a net sel...

6 days ago - The Motley Fool

Insider Sell: Amir Weiss Sells 12,300 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

Insider Sell: Amir Weiss Sells 12,300 Shares of Teva Pharmaceutical Industries Ltd (TEVA)

6 days ago - GuruFocus

3 Things You Need to Know if You Buy Teva Pharmaceutical Stock Today

Teva Pharmaceutical is more complex than you may realize, even though that's part of the company's plan.

7 days ago - The Motley Fool

TEVA's Subsidiary Grants License to Sagimet for Innovative Drug Development

TEVA's Subsidiary Grants License to Sagimet for Innovative Drug Development

8 days ago - GuruFocus

JP Morgan Raises Price Target for TEVA to $35, Maintains Overweight Rating | TEVA Stock News

JP Morgan Raises Price Target for TEVA to $35, Maintains Overweight Rating | TEVA Stock News

9 days ago - GuruFocus

Should You Forget Teva Pharmaceutical and Buy These Unstoppable Stocks Instead?

Teva Pharmaceutical is a leader in generic drugs, but these struggling makers of branded drugs may be a better choice.

10 days ago - The Motley Fool

Teva Pharmaceutical (TEVA) to Remove Over 200 Patents from FDA's Orange Book

Teva Pharmaceutical (TEVA) to Remove Over 200 Patents from FDA's Orange Book

14 days ago - GuruFocus

Teva (TEVA) Requests FDA to Remove Over 200 Patent Listings

Teva (TEVA) Requests FDA to Remove Over 200 Patent Listings

14 days ago - GuruFocus

TEVA Stock Rating Update: B of A Securities Raises Price Target to $32 | TEVA Stock News

TEVA Stock Rating Update: B of A Securities Raises Price Target to $32 | TEVA Stock News

15 days ago - GuruFocus

TEVA Stock: Barclays Initiates Coverage with Overweight Rating | TEVA Stock News

TEVA Stock: Barclays Initiates Coverage with Overweight Rating | TEVA Stock News

15 days ago - GuruFocus

Teva Stock Trading Above 200- & 50-Day SMA for 2 Months: How to Play

Teva holds bullish momentum, trading above key SMAs, as branded drugs and biosimilars drive growth despite generics softness.

16 days ago - Nasdaq